Increased Incidence of Severe Adverse Events in Non-Small Cell Lung Cancer Patients with Previous Tuberculosis Episode Treated with PD-1 Inhibitors

二维码有效期 120s

摘要Lung cancer is the top cause of cancer deaths globally.Advances in immune checkpoint inhibitors(ICIs)have transformed cancer treatment,but their use in lung cancer has led to more side effects.This study examined if past pulmonary tuberculosis(TB)affects ICIs'effectiveness and safety in lung cancer treatment.We reviewed lung cancer patients treated with ICIs at Beijing Chest Hospital from January 2019 to August 2022.We compared outcomes and side effects between patients with and without prior TB.Of 116 patients(40 with TB history,76 without),prior TB didn't reduce treatment effectiveness but did increase severe side effects.Notably,older patients(≥65 years)faced a higher risk of severe side effects.Detailed cases of two patients with severe side effects underscored TB as a risk factor in lung cancer patients receiving ICIs,stressing the need for careful monitoring and personalized care.

作者 Hui Zhang ^[1] Jinfeng Yuan ^[2] Yuanyuan Xu ^[3] Mengjie Yang ^[1] Jialin Lyu ^[1] Xinjie Yang ^[1] Shuyan Sheng ^[1] Zhe Qian ^[1] Qunhui Wang ^[1] Yu Pang ^[2] Ying Hu ^[1] 学术成果认领

作者单位 Department of Medical Oncology,Beijing Chest Hospital,Capital Medical University&Beijing Tuberculosis and Thoracic Tumor Research Institute,Beijing 101149,China ^[1] Department of Bacteriology and Immunology,Beijing Key Laboratory on Drug-Resistant Tuberculosis Research,Beijing Chest Hospital,Capital Medical University/Beijing Tuberculosis&Thoracic Tumor Research Institute,Beijing 101149,China ^[2] Chinese Center for Disease Control and Prevention,Beijing 102206,China ^[3]

关键词 Lung cancer Tuberculosis Immune checkpoint inhibitors Adverse events PD-1

栏目名称 Letters to the Editor

DOI 10.3967/bes2024.119

发布时间 2024-08-26

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交